Related references
Note: Only part of the references are listed.Cancer cell invasion driven by extracellular matrix remodeling is dependent on the properties of cancer-associated fibroblasts
Shinya Neri et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment
Genichiro Ishii et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Michael Ramirez et al.
NATURE COMMUNICATIONS (2016)
Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma
Shinya Neri et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation
Tatsuya Yoshida et al.
CLINICAL CANCER RESEARCH (2015)
Metformin Sensitizes EGFR-TKI-Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal
Li Li et al.
CLINICAL CANCER RESEARCH (2014)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer
Wei Wang et al.
CLINICAL CANCER RESEARCH (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
King Pan Ng et al.
NATURE MEDICINE (2012)
Podoplanin-Positive Fibroblasts Enhance Lung Adenocarcinoma Tumor Formation: Podoplanin in Fibroblast Functions for Tumor Progression
Ayuko Hoshino et al.
CANCER RESEARCH (2011)
Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
Seiji Yano et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
A Grading System of Lung Adenocarcinomas Based on Histologic Pattern is Predictive of Disease Recurrence in Stage I Tumors
Gabriel Sica et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Fibroblasts associated with cancer cells keep enhanced migration activity after separation from cancer cells: A novel character of tumor educated fibroblasts
Genichiro Ishii et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2010)
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
David Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cancer-Associated Fibroblasts Derived from EGFR-TKI-Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs
Sheldon R. Mink et al.
MOLECULAR CANCER RESEARCH (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
Douglas W. McMillin et al.
NATURE MEDICINE (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
William Pao et al.
NATURE REVIEWS CANCER (2010)
Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Wei Wang et al.
CLINICAL CANCER RESEARCH (2009)
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Da Wei Huang et al.
NATURE PROTOCOLS (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists
Da Wei Huang et al.
NUCLEIC ACIDS RESEARCH (2009)
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
Seiji Yano et al.
CANCER RESEARCH (2008)
Visualizing spatiotemporal dynamics of multicellular cell-cycle progression
Asako Sakaue-Sawano et al.
CELL (2008)
Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma
Akikazu Kawase et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Molecular origins of cancer: Lung cancer
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity
Malathy P. V. Shekhar et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Mutations of the epidermal growth factor receptor gene in lung cancer:: Biological and clinical implications
T Kosaka et al.
CANCER RESEARCH (2004)
A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa)
S Yano et al.
CANCER SCIENCE (2003)
The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans
GJ Wright et al.
IMMUNOLOGY (2001)
Down-regulation of the macrophage lineage through interaction with OX2 (CD200)
RM Hoek et al.
SCIENCE (2000)
Share Paper
